Literature DB >> 26966416

Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma.

T Srikumar1, M Markow2, B Centeno3, S Hoffe4, J Tao5, H Fernandez6, J Strosberg7, D Shibata8.   

Abstract

Synchronous cancers of different primary origin are rare. Here, we describe the case of a patient with concomitant diagnoses of rectal adenocarcinoma and splenic marginal zone lymphoma (smzl). A 57-year-old woman initially presented with abdominal pain. Physical examination and computed tomography demonstrated massive splenomegaly, and a complete blood count revealed microcytic anemia and lymphopenia. During the subsequent evaluation, she presented with hematochezia, melena, and constipation, which prompted gastroenterology referral. Subsequent endoscopic rectal ultrasonography revealed a T3N1 moderately differentiated rectal adenocarcinoma, with computed tomography imaging of chest, abdomen, and pelvis confirming no metastasis. Thus, the cancer was classified as clinical stage T3N1M0, stage iii. Bone marrow biopsy confirmed co-existing marginal zone lymphoma, and with the clinical presentation of massive splenomegaly, a diagnosis of smzl was made. The patient's management was individually tailored for simultaneous optimal treatment of both conditions. Concurrent treatment with neoadjuvant rituximab and 5-fluorouracil chemotherapy, with external-beam radiation therapy to the pelvis, was administered, followed by surgery consisting of en bloc splenectomy and distal pancreatectomy, and low anterior resection. The patient completed a standard course of adjuvant folfox (fluorouracil-leucovorin-oxaliplatin) chemotherapy and has remained disease-free for 7 years. To our knowledge, this report is the first to specifically describe simultaneous diagnoses of locally advanced rectal cancer and smzl. We also describe the successful combined neoadjuvant treatment combination of 5-fluorouracil, rituximab, and pelvic radiation.

Entities:  

Keywords:  5-fluorouracil; Rectal cancer; neoadjuvant chemoradiation; non-Hodgkin lymphoma; rituximab

Year:  2016        PMID: 26966416      PMCID: PMC4754072          DOI: 10.3747/co.23.2711

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  34 in total

Review 1.  Splenic marginal zone lymphoma: disease features and management.

Authors:  Estella Matutes
Journal:  Expert Rev Hematol       Date:  2013-10-30       Impact factor: 2.929

2.  Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis.

Authors:  Luigi Zorcolo; Alan S Rosman; Angelo Restivo; Michele Pisano; Giuseppe R Nigri; Alessandro Fancellu; Marcovalerio Melis
Journal:  Ann Surg Oncol       Date:  2012-03-21       Impact factor: 5.344

3.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

4.  Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.

Authors:  Apostolia M Tsimberidou; Daniel Catovsky; Ellen Schlette; Susan O'Brien; William G Wierda; Hagop Kantarjian; Guillermo Garcia-Manero; Sijin Wen; Kim-Anh Do; Susan Lerner; Michael J Keating
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

5.  The F-MACHOP regimen in the treatment of aggressive non-Hodgkin's lymphomas: a single center experience in 72 patients.

Authors:  L Infanti; F Silvestri; R Fanin; F Salmaso; F Zaja; G Barillari; F Patriarca; A Geromin; M Cerno; D Damiani; M Baccarani
Journal:  Haematologica       Date:  1996 Nov-Dec       Impact factor: 9.941

6.  Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients.

Authors:  Nilima Parry-Jones; Estella Matutes; Alicja M Gruszka-Westwood; G John Swansbury; Andrew C Wotherspoon; Daniel Catovsky
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

7.  MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.

Authors:  P Mazza; P L Zinzani; M Martelli; M Fiacchini; M Bocchia; S Pileri; B Falini; M F Martelli; S Amadori; G Papa
Journal:  Leuk Lymphoma       Date:  1995-02

8.  Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Maria K Angelopoulou; Sotirios Sachanas; Flora N Kontopidou; Xanthi Yiakoumis; Stella I Kokoris; Evagelia M Dimitriadou; Maria N Dimopoulou; Maria Moschogiannis; Penelope Korkolopoulou; Marie-Christine Kyrtsonis; Marina P Siakantaris; Theodora Papadaki; Panayiotis Tsaftaridis; Eleni Plata; Helen E Papadaki; Theodoros P Vassilakopoulos
Journal:  Oncologist       Date:  2013-01-23

9.  F-MACHOP in advanced aggressive lymphoma.

Authors:  C Guglielmi; S Amadori; M Martelli; G Papa; F Mandelli
Journal:  Leuk Lymphoma       Date:  1992-06

10.  Synchronous adenocarcinoma and mantle cell lymphoma of the colon.

Authors:  Vijayalakshmi Padmanabhan; Thomas D Trainer
Journal:  Arch Pathol Lab Med       Date:  2003-02       Impact factor: 5.534

View more
  1 in total

1.  Multiple primary tumors: Colorectal carcinoma and non-Hodgkin's lymphoma.

Authors:  Diana A Pantoja Pachajoa; Marco Antonio Bruno; Fernando A Alvarez; Germán Viscido; Facundo Mandojana; Alejandro Doniquian
Journal:  Int J Surg Case Rep       Date:  2018-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.